Medcity New’s article discussing the findings from our research on which medtech corporate venture arms are the best partners:
The shift in the stage of investment and where the perceived opportunities in biotech are have had a significant impact. Pharma corporate venture investors have broadened their interest from late stage to earlier stages of investment. Priorities have also shifted from the next blockbuster drug to more personalized treatments.
One of the consistent criticisms of corporate investors is the imperfect balance between strengthening the core business and the investment target.
Read the article in its entirety here.